CJC-1295 and Ipamorelin are the two peptides most commonly requested together in growth hormone axis research, since they act through separate receptor systems that converge on the same downstream secretion pathway. This kit pairs both at 5mg each so researchers running GH-axis protocols do not need to source them from two separate listings.
HPLC certified
Independent analysis
Highest standard
Full traceability
The GH Secretagogue kit pairs CJC-1295 5mg with Ipamorelin 5mg, the two peptides most often requested together in growth hormone axis research because they act on separate receptor systems that feed into the same release pathway rather than competing for the same target.
CJC-1295 is studied for GHRH receptor activation, the first step in triggering a pulsatile growth hormone release event. Ipamorelin is studied as a selective ghrelin/GH secretagogue receptor agonist, referenced in the literature for producing less cortisol and prolactin cross-reactivity than older secretagogues, which simplifies data interpretation in GH-axis research.
Both vials ship individually labeled and independently HPLC-verified before batch release. This product is intended strictly for laboratory research use only and is not approved for human consumption.
The GH Secretagogue kit pairs CJC-1295 5mg with Ipamorelin 5mg, the two peptides most commonly requested together in growth hormone axis research, since they act through separate receptor systems that converge on the same downstream secretion pathway. This kit bundles both so researchers running GH-axis protocols do not need to source them from two separate listings.
Growth hormone secretion is regulated by two distinct receptor systems working in sequence: the GHRH receptor, which stimulates the pituitary to release growth hormone, and the ghrelin receptor, which amplifies that release while also suppressing somatostatin, the hormone that would otherwise shut the pulse down. CJC-1295 and Ipamorelin were selected for this kit specifically because each one targets one of those two systems, which is why they turn up together in growth hormone axis research more often than either does alone.
| Vial | Peptide | Strength | Research Focus |
|---|---|---|---|
| Vial 1 | CJC-1295 | 5mg | GHRH receptor activation, the initiating step in pulsatile growth hormone release. |
| Vial 2 | Ipamorelin | 5mg | Selective ghrelin/GH secretagogue receptor activation with minimal cortisol and prolactin cross-reactivity. |
CJC-1295 is a synthetic analog of growth hormone-releasing hormone. In research settings it is used to study GHRH receptor activation, the first step in the pulsatile release pathway, without the very short half-life that limits native GHRH in experimental protocols. Researchers who need extended receptor engagement instead typically move to the DAC-modified version bundled in the Extended GH / IGF kit.
Ipamorelin is studied as a selective ghrelin/GH secretagogue receptor agonist. What distinguishes it in the literature from older secretagogues like GHRP-2 or GHRP-6 is its comparatively narrow receptor selectivity, researchers reference it specifically because it produces less cortisol and prolactin cross-reactivity in in vitro and animal models, which simplifies interpreting GH-axis data without those confounding signals. That narrower profile is the specific reason Ipamorelin, rather than an older secretagogue, is paired with CJC-1295 in this kit.
Growth hormone axis research spans several related but distinct questions: how much GH is released per pulse, how frequently pulses occur, how long the elevated signal persists, and what downstream effects follow once GH reaches peripheral tissue. CJC-1295 and Ipamorelin are studied primarily for the first two questions, pulse amplitude and pulse triggering, rather than the downstream signaling questions that a compound like IGF-1 LR3 addresses. Researchers designing a full-axis protocol frequently start with this pairing before layering in additional compounds for duration or downstream-signaling research, which is one reason this kit functions as a common starting point within the broader GH-axis research category on the site.
For extended-duration GHRH engagement plus a downstream IGF-1 research angle, see Extended GH / IGF. For the earlier-generation version of this same two-receptor pairing, see the Classic Secretagogue kit (Sermorelin and GHRP-2). For a body-composition-specific variant using Tesamorelin instead, see Body-Composition. Browse the full Peptide Bundles collection for the complete lineup of multi-peptide research kits.
Both vials ship separately labeled with compound name, strength, and batch lot number, they are not co-formulated into a single solution. Each is synthesized via solid-phase peptide synthesis and independently verified through HPLC before batch release.
This product is intended strictly for laboratory research use only. It is not approved for human consumption, therapeutic application, or diagnostic purposes.
Telomerase enzyme explained: how TERT and TERC maintain telomeres, why it matters in aging and cancer research, plus RUO peptide sourcing. Read the guide.
KLOW peptide research blend is drawing attention across California's research community. Discover its composition, COA basics, and current evidence limits.
Learn what a peptide bond is, how it forms through dehydration synthesis, and why its structure matters for research peptides. Read the full guide now.
(faqs)
